A new prognostic model for predicting 30-day mortality in acute oncology patients.

INTRODUCTION: Acute oncology services (AOS) provide rapid review and expedited pathways for referral to specialist care for cancer patients. Blood tests may support AOS in providing estimates of prognosis. We aimed to develop and validate a prognostic model of 30-day mortality based on routine blood markers to inform an AOS decision to actively treat or palliate patients. METHODS AND MATERIALS: Using clinical data from 752 AOS referrals, multivariable logistic regression analysis was conducted to develop a 30-day mortality prognostic model. Internal validation and then internal-external cross-validation were used to examine overfitting and generalizability of the model's predictive performance. RESULTS: Urea, alkaline phosphatase, albumin and neutrophils were the strongest predictors of outcome. The model separated patients into distinct prognostic groups from the cross-validation (C Statistic: 0.70; 95% CI: 0.64-0.76). Admission year was included as a predictor in the model to improve the model calibration. CONCLUSION: The developed prediction model was able to classify patients into distinct prognostic risk groups, which is clinically useful for delivering an evidence-based AOS. Collation of data from other AOS centers would allow for the development of a more generalizable prognostic model.

Do Learning Disabilities Affect Testicular Cancer Survival: A National Cohort Study Between 2001 and 2015.

BACKGROUND: Some 1.5 million people in the UK have a learning disability (LD). This vulnerable group derives less benefit from population-based education programs. They are prone to underenrolment in screening programs and may lack the ability to perform self-examination. OBJECTIVE: To identify patients with LD in England and assess their testicular cancer (TC) survival in comparison to the general population. DESIGN, SETTING, AND PARTICIPANTS: Patient records were identified from the Hospital Episode Statistics database. All patients resident in England with a diagnosis of mental debility, "developmental disorder of scholastic skills", or attending under the specialty of LD between April 1, 2001 and June 30, 2015 were included. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We measured survival outcomes according to the Kaplan-Meier method and used log-rank tests to assess survival difference between demographic groups. RESULTS AND LIMITATIONS: Of 158138 male patients with LD, 331 had TC and 32 died of cancer. LD patients had a poorer prognosis, with 10-yr TC-specific survival of 88.4% (95% confidence interval [CI] 84.5-92.4%) in the LD group versus 96.8% (95% CI 96.6-97.1%) in the non-LD group. LD patients also had lower all-cause survival rates. The 10-yr survival rate was 77.6% (95% CI 72.2-83.3%) for LD patients versus 89.9% (95% CI 89.4-90.3%) for non-LD patients, while the corresponding 5-yr rates were 84% (95% CI 79.9-88.4%) versus 92.2% (95% CI 91.8-92.5%). CONCLUSIONS: Education regarding self-examination for TC must be provided in a format suitable for those with LD. Carers for male patients with LD should be informed about testicular examination and sinister signs. PATIENT SUMMARY: Testicular cancer patients who also have a learning disability (LD) have a one in nine chance of dying, compared to a one in 36 chance for testicular cancer patients without LD. This is because patients with LD are less likely to detect the disease at an earlier stage.

Molecular neuro-oncology: a forward-looking perspective.

Professor Wolfgang Wick speaks to Tess O'Neill, Head of Commissioning: Wolfgang Wick is the Chairman of the Department of Neuro-Oncology, Hertie Professor of Neuro-Oncology and Director at the National Tumor Center at the University of Heidelberg, Germany. He is conducting multicenter Phase III randomized trials for the Neuro-Oncology Working Group of the German Cancer Society, the European Organisation for Research and Treatment of Cancer as well as a number of multicenter trials with the pharmaceutical industry. He is a steering committee member of the Neuro-Oncology Working Group and the European Association for Neuro-oncology as well as chairman of the European Organisation for Research and Treatment of Cancer Brain Tumor Group. His main scientific interests include migration and invasion of glioma cells, biomarkers and radiosensitization.

Recent advances in hematology: an update from the 16th Congress of the EHA.

The burden of hematological disorders on healthcare providers is reaching a new peak as the population continues to age, making current research and debate in hematology arguably of greater importance than ever before. At the 16th Congress of the European Hematology Association in London, UK, the latest advances in research, and their associated clinical implications, were highlighted. This article provides a brief overview of a selection of presentations taken from the extensive program.